Phase II Completed Licensing Opportunity

ENERGI-F701

Fast and effective treatment for male and female hair loss

Asset Brief

- ✓ **Target disease:** female hair loss, Androgenic alopecia
- ✓ **Molecular type:** Small molecule compound
- ✓ **Route:** Topical tonic
- ✓ **Development status:** Phase II completed
- ✓ **Cooperation model:** Licensing or Co-development

ATP Level in Human follicle dermal papilla cells (HFDPCs)



MOA

- ✓ Maintain the hair cycle by elevating cellular ATP level and suppress the synthesis of TGF-b2 (to prevent cell death in germinative matrix cells).

Marketing Position

- ✓ ENERGI-F701 fulfills the unmet medical need for women's hair loss; using minoxidil will experience early stage hair loss.
- ✓ ENERGI-F701 demonstrated earlier onset (at week 4) of hair loss reduction than 2% Minoxidil that differentiates from current treatments.-

ENERGI-F701 lessens the DHT suppression and TGF-b2 synthesis to promote hair growth in mice model



Fig. C57BL/6 mice were denuded using animal clippers and hair removal cream. DHT and indicated reagents were topically applied to the back skin daily for 16 days.

ENERGI-F701 shows fast onset in reducing hair loss than 2% Minoxidil in female patients



Contact

partnership@energenesis-biomedical.com

Energenesis Biomedical

Phase II Completed Licensing Opportunity

ENERGI-F703

First-in-Class, best in class Drug for Wound Healing in **Diabetic Foot Ulcer (DFU)**

Asset Brief

- ✓ **Target disease:** Diabetic Foot Ulcer (DFU)
- ✓ **Molecular type:** Small molecule compound
- ✓ **Route:** Topical gel
- ✓ **Development status:** Phase II completed
- ✓ **Cooperation model:** Licensing or co-development on phase 3 trial

ATP Level in db/db mice model



MOA

- ✓ Accelerate wound healing by elevating cellular ATP level.

Marketing Position

- ✓ The current market share of the only DFU drug in global market is less than 1%; achieving fast wound healing associates with lower incidence of long-term clinical remission and improve standard DFU care.
- ✓ ENERGI-F703 is a proof of concept to accelerate wound healing and may become the drug of choice in DFU patients.

ENERGI-F703 significantly improves the ulcer closure by week 12



Wagner grade 1 to 2 ; Ulcer size: 1 to 25 cm^2

ENERGI-F703 accelerates wound healing especially in severe wounds



Contact

partnership@energenesis-biomedical.com

Energenesis Biomedical

Preclinical Stage Licensing Opportunity

ENERGI-F704

First-in-Class Drug for Mucosal Wound Healing in **Inflammatory Bowel Disease (IBD)**

Asset Brief

- ✓ **Target disease:** Inflammatory Bowel Disease (IBD)
- ✓ **Molecular type:** small molecule compound
- ✓ **Route:** oral
- ✓ **Development status:** Pre-clinical
- ✓ **Cooperation model:** Licensing or Co-development

ATP Level in Colonic Tissue



MOA

- ✓ Accelerating mucosal wound healing by elevating cellular ATP level

Marketing Position

- ✓ The **IBD** drugs in global market have limitations in the long term of clinical remission; achieving mucosal healing associates with lower incidence of long-term clinical remission.
- ✓ **ENERGI-F704** can accelerate mucosal healing and may offer an improvement in clinical remission of IBD.

ENERGI-F704 improves IBD disease activity Index (DAI)



ENERGI-F704 accelerates mucosal wound healing



Contact

partnership@energenesis-biomedical.com

Energenesis Biomedical

Preclinical Stage Licensing Opportunity

ENERGI-F705

Disease modifying treatment for Parkinson's Disease

Asset Brief

- ✓ **Target disease:** Parkinson's Disease
- ✓ **Molecular type:** small molecule compound
- ✓ **Route:** oral
- ✓ **Development status:** Pre-clinical; phase 1 in late 2020
- ✓ **Cooperation model:** Out-Licensing or co-development



Mechanism of Action

- ✓ Upregulate the expression of tyrosine hydroxylase (TH) and dopamine production.
- ✓ Prevent protein aggregation by elevating cellular ATP level.

Marketing Position

- ✓ Current Parkinson's disease drugs in global market cannot delay disease progression, there are unmet needs for neuroprotective and disease-modifying agents.
- ✓ **ENERGI-F705** can increase dopamine production, reverse Paraquat induced PD symptom and maintain the motor neuron integrity which may be a disease modify drug.
- ✓ First-in-class drug to target protein aggregation in treating Parkinson's disease.

ENERGI-F705 upregulated dopamine production in striatum of C57/B6 mice



ENERGI-F705 improves the behavior of the 6-OHDA lesioned C57/B6 mice



Contact:
partnership@energenesis-biomedical.com

Energenesis Biomedical